SCHEMBL20116945

SCHEMBL20116945

CC(C)(C)OC(=O)N1CCC(c2nc(-c3ccnc(Cl)c3)no2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.52
LMNA P02545 1/20 0.50
TSHR P16473 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
FAAH O00519 2/20 0.47
EPHA2 P29317 1/20 0.46
KDR P35968 1/20 0.46
EPHB4 P54760 1/20 0.46
HDAC4 P56524 1/20 0.46
GRM5 P41594 1/20 0.46
TUBB4A P04350 1/20 0.45
TUBB P07437 1/20 0.45
TUBA3C P0DPH7 1/20 0.45
TUBA1B P68363 1/20 0.45
TUBA4A P68366 1/20 0.45
TUBB4B P68371 1/20 0.45
TUBB3 Q13509 1/20 0.45
TUBB2A Q13885 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20116338 0.89 LMNA (0.53) LMNATSHRSMN1; SMN2HCRTR1HCRTR2
SCHEMBL32676791 0.86 EPHA2 (0.52) GPR119LMNATSHRSMN1; SMN2EPHA2
SCHEMBL390646 0.86 GPR119 (0.67) GPR119LMNATSHRSMN1; SMN2HDAC4
SCHEMBL4419288 0.85 LMNA (0.59) GPR119LMNATSHRSMN1; SMN2FAAH
SCHEMBL20676504 0.84 GPR119 (0.47) GPR119LMNATSHRSMN1; SMN2HDAC4
SCHEMBL1653518 0.83 TUBB4A (0.60) GPR119LMNATSHRSMN1; SMN2FAAH
SCHEMBL23411281 0.82 GRM5 (0.60) GRM5
SCHEMBL29891703 0.82 GRM5 (0.60) GRM5
SCHEMBL4423384 0.82 GPR119 (0.59) GPR119LMNATSHRSMN1; SMN2HDAC4
SCHEMBL12580575 0.81 GPR119 (0.54) GPR119LMNATSHRSMN1; SMN2HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 US disclosed
US-20200262828-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2020-08-20 US disclosed
WO-2019209948-A9 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. (US) 2020-01-02 WO disclosed
WO-2019018795-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2019-01-24 WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 GPR119 2922/4885LMNA 1966/4885TSHR 4679/4885
US-20200262828-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 GPR119 2922/4885LMNA 1966/4885TSHR 4679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.